Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 220

1.

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.

Grosser R, Cherkassky L, Chintala N, Adusumilli PS.

Cancer Cell. 2019 Nov 11;36(5):471-482. doi: 10.1016/j.ccell.2019.09.006. Review.

PMID:
31715131
2.

Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy.

Li X, Eguchi T, Aly RG, Chintala NK, Tan KS, Zauderer MG, Dembitzer FR, Beasley MB, Ghebrehiwet B, Adusumilli PS, Peerschke EIB.

Front Oncol. 2019 Oct 11;9:1042. doi: 10.3389/fonc.2019.01042. eCollection 2019.

3.

Predicting spread through air spaces (STAS) preoperatively: can imaging help?

Johnston RP, Emoto K, Dux J, Travis WD, Adusumilli PS.

J Thorac Dis. 2019 Sep;11(Suppl 15):S1938-S1941. doi: 10.21037/jtd.2019.08.77. No abstract available.

4.

Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis.

Choe G, Ghanie A, Riely G, Rimner A, Park BJ, Bains MS, Rusch VW, Adusumilli PS, Downey RJ, Jones DR, Huang J.

J Thorac Cardiovasc Surg. 2019 Sep 13. pii: S0022-5223(19)31772-6. doi: 10.1016/j.jtcvs.2019.08.037. [Epub ahead of print]

PMID:
31610957
5.
6.

V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.

Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.

Mod Pathol. 2019 Sep 19. doi: 10.1038/s41379-019-0364-z. [Epub ahead of print]

PMID:
31537897
7.

Prevalence of occult peribronchial N1 nodal metastasis in peripheral clinical N0 <2 cm NSCLC.

Robinson EM, Ilonen IK, Tan KS, Plodkowski AJ, Bott M, Bains MS, Adusumilli PS, Park BJ, Rusch VW, Jones DR, Huang J.

Ann Thorac Surg. 2019 Aug 31. pii: S0003-4975(19)31262-7. doi: 10.1016/j.athoracsur.2019.07.037. [Epub ahead of print]

PMID:
31479639
8.

Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma.

Zhou J, Sanchez-Vega F, Caso R, Tan KS, Brandt WS, Jones GD, Yan S, Adusumilli PS, Bott M, Huang J, Isbell JM, Sihag S, Molena D, Rusch VW, Chatila WK, Rekhtman N, Yang F, Ladanyi M, Solit DB, Berger MF, Schultz N, Jones DR.

Clin Cancer Res. 2019 Aug 27. doi: 10.1158/1078-0432.CCR-19-1651. [Epub ahead of print]

PMID:
31455678
9.

Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas.

Emoto K, Eguchi T, Tan KS, Takahashi Y, Aly RG, Rekhtman N, Travis WD, Adusumilli PS.

J Thorac Oncol. 2019 Nov;14(11):1948-1961. doi: 10.1016/j.jtho.2019.07.008. Epub 2019 Jul 25.

PMID:
31352072
10.

Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations.

Zauderer MG, Jayakumaran G, DuBoff M, Zhang L, Francis JH, Abramson DH, Cercek A, Nash GM, Shoushtari A, Chapman P, D'Angelo S, Arnold AG, Siegel B, Fleischut MH, Ni A, Rimner A, Rusch VW, Adusumilli PS, Travis W, Sauter JL, Zehir A, Mandelker D, Ladanyi M, Robson M.

J Thorac Oncol. 2019 Nov;14(11):1989-1994. doi: 10.1016/j.jtho.2019.07.002. Epub 2019 Jul 16.

PMID:
31323388
11.

Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.

Carbone M, Adusumilli PS, Alexander HR Jr, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HI.

CA Cancer J Clin. 2019 Sep;69(5):402-429. doi: 10.3322/caac.21572. Epub 2019 Jul 8. Review.

12.

Commentary: Return to intended radiation therapy-Criteria for resection?

Dux J, Grosser R, Adusumilli PS.

J Thorac Cardiovasc Surg. 2019 Sep;158(3):930-931. doi: 10.1016/j.jtcvs.2019.04.050. Epub 2019 Apr 30. No abstract available.

PMID:
31160109
13.

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.

Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJ Jr.

J Thorac Oncol. 2019 Aug;14(8):1343-1353. doi: 10.1016/j.jtho.2019.04.029. Epub 2019 May 25. Review.

PMID:
31136816
14.

Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.

Aly RG, Rekhtman N, Li X, Takahashi Y, Eguchi T, Tan KS, Rudin CM, Adusumilli PS, Travis WD.

J Thorac Oncol. 2019 Sep;14(9):1583-1593. doi: 10.1016/j.jtho.2019.05.009. Epub 2019 May 20.

PMID:
31121325
15.

Early Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy.

Sarkaria IS, Rizk NP, Goldman DA, Sima C, Tan KS, Bains MS, Adusumilli PS, Molena D, Bott M, Atkinson T, Jones DR, Rusch VW.

Ann Thorac Surg. 2019 Sep;108(3):920-928. doi: 10.1016/j.athoracsur.2018.11.075. Epub 2019 Apr 23.

PMID:
31026433
16.

Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma.

Kim TH, Buonocore D, Petre EN, Durack JC, Maybody M, Johnston RP, Travis WD, Adusumilli PS, Solomon SB, Ziv E.

Ann Thorac Surg. 2019 Aug;108(2):392-398. doi: 10.1016/j.athoracsur.2019.03.043. Epub 2019 Apr 12.

PMID:
30986416
17.

Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non-small cell lung cancer.

Latif MJ, Tan KS, Molena D, Huang J, Bott MJ, Park BJ, Adusumilli PS, Rusch VW, Bains MS, Downey RJ, Jones DR, Isbell JM.

J Thorac Cardiovasc Surg. 2019 Jun;157(6):2469-2477.e10. doi: 10.1016/j.jtcvs.2018.12.109. Epub 2019 Feb 12.

PMID:
30902468
18.

Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.

Bott MJ, Yang SC, Park BJ, Adusumilli PS, Rusch VW, Isbell JM, Downey RJ, Brahmer JR, Battafarano R, Bush E, Chaft J, Forde PM, Jones DR, Broderick SR.

J Thorac Cardiovasc Surg. 2019 Jul;158(1):269-276. doi: 10.1016/j.jtcvs.2018.11.124. Epub 2018 Dec 13.

PMID:
30718052
19.

Unique Considerations for Females Undergoing Esophagectomy.

Nobel TB, Livschitz J, Eljalby M, Janjigian YY, Bains MS, Adusumilli PS, Jones DR, Molena D.

Ann Surg. 2019 Jan 18. doi: 10.1097/SLA.0000000000003202. [Epub ahead of print]

PMID:
30672802
20.

Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.

Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, Tan KS, Jones DR, Kris MG, Adusumilli PS, Travis WD.

J Thorac Oncol. 2019 Mar;14(3):482-493. doi: 10.1016/j.jtho.2018.11.017. Epub 2018 Nov 29.

PMID:
30503889
21.

Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance.

Takahashi Y, Eguchi T, Kameda K, Lu S, Vaghjiani RG, Tan KS, Travis WD, Jones DR, Adusumilli PS.

Oncotarget. 2018 Nov 6;9(87):35742-35751. doi: 10.18632/oncotarget.26285. eCollection 2018 Nov 6.

22.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.

Brandt WS, Yan W, Zhou J, Tan KS, Montecalvo J, Park BJ, Adusumilli PS, Huang J, Bott MJ, Rusch VW, Molena D, Travis WD, Kris MG, Chaft JE, Jones DR.

J Thorac Cardiovasc Surg. 2019 Feb;157(2):743-753.e3. doi: 10.1016/j.jtcvs.2018.09.098. Epub 2018 Oct 10.

PMID:
30415902
23.

Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Nov;13(11):1655-1667. doi: 10.1016/j.jtho.2018.08.2036. Epub 2018 Sep 25.

24.

Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis.

Bains S, Eguchi T, Warth A, Yeh YC, Nitadori JI, Woo KM, Chou TY, Dienemann H, Muley T, Nakajima J, Shinozaki-Ushiku A, Wu YC, Lu S, Kadota K, Jones DR, Travis WD, Tan KS, Adusumilli PS.

J Thorac Oncol. 2019 Jan;14(1):72-86. doi: 10.1016/j.jtho.2018.09.008. Epub 2018 Sep 22.

PMID:
30253972
25.

Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis.

Eguchi T, Kameda K, Lu S, Bott MJ, Tan KS, Montecalvo J, Chang JC, Rekhtman N, Jones DR, Travis WD, Adusumilli PS.

J Thorac Oncol. 2019 Jan;14(1):87-98. doi: 10.1016/j.jtho.2018.09.005. Epub 2018 Sep 19.

PMID:
30244070
26.

Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma.

Kameda K, Eguchi T, Lu S, Qu Y, Tan KS, Kadota K, Adusumilli PS, Travis WD.

J Thorac Oncol. 2018 Dec;13(12):1919-1929. doi: 10.1016/j.jtho.2018.08.2022. Epub 2018 Sep 7.

PMID:
30195703
27.

Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer.

Brandt WS, Yan W, Leeman JE, Tan KS, Park BJ, Adusumilli PS, Bott MJ, Molena D, Isbell J, Chaft J, Rimner A, Jones DR.

Ann Thorac Surg. 2018 Sep;106(3):848-855. doi: 10.1016/j.athoracsur.2018.04.064. Epub 2018 May 26.

28.

Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients: A Propensity Score Matched Competing Risks Analysis.

Hristov B, Eguchi T, Bains S, Dycoco J, Tan KS, Isbell JM, Park BJ, Jones DR, Adusumilli PS.

Ann Surg. 2019 Dec;270(6):1161-1169. doi: 10.1097/SLA.0000000000002772.

PMID:
29672399
29.

What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?

Aherne EA, Plodkowski AJ, Montecalvo J, Hayan S, Zheng J, Capanu M, Adusumilli PS, Travis WD, Ginsberg MS.

Lung Cancer. 2018 Apr;118:83-89. doi: 10.1016/j.lungcan.2018.01.013. Epub 2018 Feb 3.

30.

Driving CARs on the uneven road of antigen heterogeneity in solid tumors.

Chen N, Li X, Chintala NK, Tano ZE, Adusumilli PS.

Curr Opin Immunol. 2018 Apr;51:103-110. doi: 10.1016/j.coi.2018.03.002. Epub 2018 Mar 16. Review.

31.

Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors.

Bott MJ, Cools-Lartigue J, Tan KS, Dycoco J, Bains MS, Downey RJ, Huang J, Isbell JM, Molena D, Park BJ, Rusch VW, Sihag S, Jones DR, Adusumilli PS.

Ann Thorac Surg. 2018 Jul;106(1):178-183. doi: 10.1016/j.athoracsur.2018.02.030. Epub 2018 Mar 14.

32.

Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma.

Barbetta A, Hsu M, Tan KS, Stefanova D, Herman K, Adusumilli PS, Bains MS, Bott MJ, Isbell JM, Janjigian YY, Ku GY, Park BJ, Wu AJ, Jones DR, Molena D.

J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3. doi: 10.1016/j.jtcvs.2018.01.086. Epub 2018 Feb 15.

33.

Competing risks and cancer-specific mortality: why it matters.

Tan KS, Eguchi T, Adusumilli PS.

Oncotarget. 2017 Dec 28;9(7):7272-7273. doi: 10.18632/oncotarget.23729. eCollection 2018 Jan 26. No abstract available.

34.

Tracing the origin, tracking the evolution, and the treatment of the future.

Emoto K, Vaghjiani RG, Adusumilli PS.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1203-1204. doi: 10.1016/j.jtcvs.2017.12.024. Epub 2017 Dec 9. No abstract available.

PMID:
29452466
35.

Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.

Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS.

Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052. Review.

36.

Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study.

Rosen LE, Karrison T, Ananthanarayanan V, Gallan AJ, Adusumilli PS, Alchami FS, Attanoos R, Brcic L, Butnor KJ, Galateau-Sallé F, Hiroshima K, Kadota K, Klampatsa A, Stang NL, Lindenmann J, Litzky LA, Marchevsky A, Medeiros F, Montero MA, Moore DA, Nabeshima K, Pavlisko EN, Roggli VL, Sauter JL, Sharma A, Sheaff M, Travis WD, Vigneswaran WT, Vrugt B, Walts AE, Tjota MY, Krausz T, Husain AN.

Mod Pathol. 2018 Apr;31(4):598-606. doi: 10.1038/modpathol.2017.170. Epub 2018 Jan 12.

37.

Micropapillary lung adenocarcinoma and micrometastasis.

Qu Y, Aly RG, Takahashi Y, Adusumilli PS.

J Thorac Dis. 2017 Oct;9(10):3443-3446. doi: 10.21037/jtd.2017.09.62. No abstract available.

38.

Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma.

Brandt WS, Bouabdallah I, Tan KS, Park BJ, Adusumilli PS, Molena D, Bains MS, Huang J, Isbell JM, Bott MJ, Jones DR.

J Thorac Cardiovasc Surg. 2018 Mar;155(3):1212-1224.e3. doi: 10.1016/j.jtcvs.2017.09.151. Epub 2017 Nov 13.

39.

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies.

Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS.

J Thorac Oncol. 2018 Jan;13(1):16-26. doi: 10.1016/j.jtho.2017.10.001. Epub 2017 Oct 26. Review. Erratum in: J Thorac Oncol. 2018 Aug;13(8):1229.

40.

New staging system for pulmonary neuroendocrine tumors: A clinical and pathologic necessity.

Lee MC, Aly RG, Adusumilli PS.

J Thorac Cardiovasc Surg. 2018 Jan;155(1):367-368. doi: 10.1016/j.jtcvs.2017.09.068. Epub 2017 Sep 22. No abstract available.

PMID:
29102207
41.

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.

Eguchi T, Kadota K, Mayor M, Zauderer MG, Rimner A, Rusch VW, Travis WD, Sadelain M, Adusumilli PS.

Oncotarget. 2017 Sep 12;8(44):77872-77882. doi: 10.18632/oncotarget.20845. eCollection 2017 Sep 29.

42.

BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.

Bucciarelli PR, Tan KS, Chudgar NP, Brandt W, Montecalvo J, Eguchi T, Liu Y, Aly R, Travis WD, Adusumilli PS, Jones DR.

J Thorac Oncol. 2018 Jan;13(1):73-84. doi: 10.1016/j.jtho.2017.10.006. Epub 2017 Oct 31. Erratum in: J Thorac Oncol. 2019 Jun;14(6):1109.

43.

Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?

Chudgar NP, Brennan MF, Tan KS, Munhoz RR, D'Angelo SP, Bains MS, Huang J, Park BJ, Adusumilli PS, Tap WD, Jones DR.

Ann Thorac Surg. 2017 Dec;104(6):1837-1845. doi: 10.1016/j.athoracsur.2017.07.024. Epub 2017 Nov 2.

44.

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.

Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM.

Clin Cancer Res. 2017 Dec 15;23(24):7483-7489. doi: 10.1158/1078-0432.CCR-17-2169. Epub 2017 Sep 28.

45.

Immunotherapy for Non-Small Cell Lung Cancer: A Therapy for All Stages?

Aly RG, Vaghjiani RG, Adusumilli PS.

Semin Thorac Cardiovasc Surg. 2017 Autumn;29(3):416-417. doi: 10.1053/j.semtcvs.2017.08.014. Epub 2017 Aug 24. No abstract available.

PMID:
28967537
46.

The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.

Amin EM, Liu Y, Deng S, Tan KS, Chudgar N, Mayo MW, Sanchez-Vega F, Adusumilli PS, Schultz N, Jones DR.

Sci Signal. 2017 Sep 19;10(497). pii: eaah3941. doi: 10.1126/scisignal.aah3941.

47.

Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma.

Takahashi Y, Eguchi T, Lu S, Downey RJ, Jones DR, Travis WD, Adusumilli PS.

Am J Respir Crit Care Med. 2018 Mar 15;197(6):816-818. doi: 10.1164/rccm.201705-0924LE. No abstract available.

48.

Erratum to: Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Gao S, Stein S, Petre EN, Shady W, Durack JC, Ridge C, Adusumilli PS, Rekhtman N, Solomon SB, Ziv E.

Cardiovasc Intervent Radiol. 2017 Oct;40(10):1658. doi: 10.1007/s00270-017-1767-1. No abstract available.

PMID:
28799111
49.

Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28.

Chicaybam L, Adusumilli PS.

Transl Cancer Res. 2017 Aug;6(Suppl 6):S1080-S1083. doi: 10.21037/tcr.2017.08.05. No abstract available.

50.

Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Dozier J, Zheng H, Adusumilli PS.

Transl Lung Cancer Res. 2017 Jun;6(3):315-324. doi: 10.21037/tlcr.2017.05.02. Review.

Supplemental Content

Loading ...
Support Center